List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Gastric Ulcers - Overview
Gastric Ulcers - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Gastric Ulcers - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Gastric Ulcers - Companies Involved in Therapeutics Development
Axsome Therapeutics Inc
Daewoong Pharmaceutical Co Ltd
FortuneRock (China) Ltd
Hunan Mingrui Pharmaceutical Co Ltd
Hunan Sailong Pharmaceutical Co Ltd
Jiangsu Aosaikang Pharmaceutical Co Ltd
Korea Pharma Co Ltd
Kukje Pharmaceutical Industry Co Ltd
PharmaKing Co Ltd
RaQualia Pharma Inc
XuanZhu Biological Technology Co Ltd
Gastric Ulcers - Drug Profiles
(meloxicam + esomeprazole) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dexlansoprazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dexlansoprazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fexuprazan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INT-2150 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KBP-3571 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KP-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pantoprazole sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PMKS-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SFR-9X0123 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit COX-2 for Gastric Ulcers, Inflammation and Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tegoprazan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gastric Ulcers - Dormant Projects
Gastric Ulcers - Discontinued Products
Gastric Ulcers - Product Development Milestones
Featured News & Press Releases
Jul 17, 2013: Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies
Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck
Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations
Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy
Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc.
Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium)
Jun 01, 2007: AstraZeneca's Prilosec Patents Upheld By Court
Dec 12, 2003: Astrazeneca Prilosec Patents Upheld by Federal Appeals Court
Aug 08, 2003: Astrazeneca to Seek Triple Damages in Patent Infringement Lawsuit Against Mylan Pharmaceuticals
Oct 23, 2001: Prilosec US litigation
May 02, 2001: Astrazeneca Receives Six Months' Market Exclusivity for Prilosec
May 02, 2001: Court Denies Generic's Application for Summary Judgement on Prilosec Patent
Apr 23, 2001: Astrazeneca Files Lawsuit Against Apotex Corporation and Torpharm for Patent Infringement
Dec 19, 2000: Astrazeneca Wins Losec Patent Litigation in Canada
Oct 20, 2000: Joint FDA Advisory Committee Confirms OTC Prilosec (Omeprazole) Safety and Efficacy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Gastric Ulcers, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Gastric Ulcers - Pipeline by Axsome Therapeutics Inc, 2021
Gastric Ulcers - Pipeline by Daewoong Pharmaceutical Co Ltd, 2021
Gastric Ulcers - Pipeline by FortuneRock (China) Ltd, 2021
Gastric Ulcers - Pipeline by Hunan Mingrui Pharmaceutical Co Ltd, 2021
Gastric Ulcers - Pipeline by Hunan Sailong Pharmaceutical Co Ltd, 2021
Gastric Ulcers - Pipeline by Jiangsu Aosaikang Pharmaceutical Co Ltd, 2021
Gastric Ulcers - Pipeline by Korea Pharma Co Ltd, 2021
Gastric Ulcers - Pipeline by Kukje Pharmaceutical Industry Co Ltd, 2021
Gastric Ulcers - Pipeline by PharmaKing Co Ltd, 2021
Gastric Ulcers - Pipeline by RaQualia Pharma Inc, 2021
Gastric Ulcers - Pipeline by XuanZhu Biological Technology Co Ltd, 2021
Gastric Ulcers - Dormant Projects, 2021
Gastric Ulcers - Dormant Projects, 2021 (Contd..1)
Gastric Ulcers - Discontinued Products, 2021

List of Figures
Number of Products under Development for Gastric Ulcers, 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

Companies Mentioned
• Axsome Therapeutics Inc
• Daewoong Pharmaceutical Co Ltd
• FortuneRock (China) Ltd
• Hunan Mingrui Pharmaceutical Co Ltd
• Hunan Sailong Pharmaceutical Co Ltd
• Jiangsu Aosaikang Pharmaceutical Co Ltd
• Korea Pharma Co Ltd
• Kukje Pharmaceutical Industry Co Ltd
• PharmaKing Co Ltd
• RaQualia Pharma Inc
• XuanZhu Biological Technology Co Ltd